Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proteomics in clinical trials and practice: present uses and future promise.
Azad NS, Rasool N, Annunziata CM, Minasian L, Whiteley G, Kohn EC. Azad NS, et al. Among authors: annunziata cm. Mol Cell Proteomics. 2006 Oct;5(10):1819-29. doi: 10.1074/mcp.R600008-MCP200. Epub 2006 May 30. Mol Cell Proteomics. 2006. PMID: 16737951 Free article. Review.
Proteomics as a tool for biomarker discovery.
Kohn EC, Azad N, Annunziata C, Dhamoon AS, Whiteley G. Kohn EC, et al. Dis Markers. 2007;23(5-6):411-7. doi: 10.1155/2007/967023. Dis Markers. 2007. PMID: 18057524 Free PMC article. Review.
Ovarian cancer in the proteomics era.
Annunziata CM, Azad N, Dhamoon AS, Whiteley G, Kohn EC. Annunziata CM, et al. Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:1-6. doi: 10.1111/j.1525-1438.2007.01096.x. Int J Gynecol Cancer. 2008. PMID: 18336391 Review.
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC. Azad NS, et al. Among authors: annunziata cm. J Clin Oncol. 2008 Aug 1;26(22):3709-14. doi: 10.1200/JCO.2007.10.8332. J Clin Oncol. 2008. PMID: 18669456 Free PMC article. Clinical Trial.
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.
Annunziata CM, Walker AJ, Minasian L, Yu M, Kotz H, Wood BJ, Calvo K, Choyke P, Kimm D, Steinberg SM, Kohn EC. Annunziata CM, et al. Clin Cancer Res. 2010 Jan 15;16(2):664-72. doi: 10.1158/1078-0432.CCR-09-2308. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068097 Free PMC article. Clinical Trial.
115 results